ESR1 XbaI — How This Estrogen Receptor Variant Shapes Reproductive Outcomes
Estrogen receptor alpha (ERα), encoded by ESR1 on chromosome 6, is the master mediator of
estrogen signaling across reproductive tissues, bone, brain, and the cardiovascular system.
When estrogen binds ERα, the receptor dimerizes, translocates to gene promoters, and drives
transcription of hundreds of downstream targets governing menstrual cyclicity, endometrial
receptivity, follicular growth, and uterine function. The rs9340799 XbaI polymorphism — an
A-to-G substitution deep in the first intron of ESR1 — does not change the receptor's
amino acid sequence, but accumulating evidence suggests it influences receptor expression
levels and estrogen-signaling efficiency in reproductive tissues.
The variant earned its name from the restriction enzyme XbaI: the A allele creates a
recognition site that is cut by XbaI, while the G allele abolishes this site. Because
it sits in an intron and has been studied extensively by RFLP genotyping, the literature
uses two parallel naming conventions — the "XbaI A/G" allele system (used here, as it
corresponds to the plus-strand GRCh38 alleles) and the older "X/x" uppercase/lowercase
notation where uppercase X denotes absence of the restriction site (the G allele).
The Mechanism
rs9340799 lies within intron 1 of ESR1, a region that contains regulatory elements
influencing transcription and alternative splicing. The A>G change is in strong
linkage disequilibrium | LD means the two variants are inherited together so often that
knowing one predicts the other with the
adjacent PvuII polymorphism (rs2234693), and both are typically analyzed as a haplotype.
The G allele at rs9340799 disrupts predicted regulatory motifs and appears to reduce
baseline ERα expression in endometrial tissue relative to the A allele, which may alter
estrogen sensitivity during the implantation window.
The precise molecular mechanism remains incompletely characterized. The variant may act
through altered splicing efficiency, effects on enhancer activity, or changes to the
local chromatin environment. Crucially, the same G allele that reduces endometrial
estrogen responsiveness may paradoxically protect against bone fractures (potentially
via altered bone-specific ERα isoform expression) and against male infertility —
illustrating how tissue-specific regulatory effects can produce direction-switching
outcomes across biological contexts.
The Evidence
Endometriosis and IVF outcomes:
A
Brazilian case-control study (98 endometriosis patients, 115 IVF-failure patients, 134
fertile controls) | Paskulin et al. Disease Markers, 2013
found that the GG genotype was strongly associated with endometriosis-related infertility
(OR 4.67, 95% CI 1.84–11.83, P = 0.001) and with IVF failure (OR 3.33, 95% CI 1.38–8.03,
P = 0.007). In the same cohort, the AA genotype was significantly more common in fertile
controls, suggesting the A allele supports normal endometrial function.
Consistent with this, a
cross-sectional IVF study of 136 Brazilian infertile women | de Mattos et al. Journal of
Ovarian Research, 2014 found the AA genotype
was associated with significantly more follicles, more mature oocytes, and better embryo
quality during controlled ovarian hyperstimulation — suggesting the A allele confers
superior ovarian responsiveness to FSH stimulation.
Premature ovarian insufficiency:
An
Iranian case-control study (150 POI cases, 150 controls under age 35) | Eshaghi et al.
International Journal of Reproductive Biomedicine, 2022
found significant associations between rs9340799 genotypes and premature ovarian
insufficiency. The T(PvuII)/A(XbaI) haplotype (i.e., carrying the rs2234693 T allele
with the rs9340799 A allele) was identified as a risk haplotype for POI, suggesting
complex genotype × context effects at this locus.
Severe pre-eclampsia:
A
meta-analysis of seven studies | Zhao et al. Bioscience Reports, 2019
found the GG genotype was associated with elevated severe pre-eclampsia risk
(OR 1.67, 95% CI 1.10–2.25, P = 0.017), while neither genotype was associated
with mild pre-eclampsia. The evidence is modest given the small number of constituent
studies and limited statistical power.
Fractures:
The large
GENOMOS consortium study of 18,917 individuals across eight European centers | Ioannidis
et al. JAMA, 2004 found that the GG genotype
(absent XbaI site) was associated with a 19% reduction in all fractures (OR 0.81, P = 0.002)
and a 35% reduction in vertebral fractures (OR 0.65, P = 0.003) — an effect independent
of bone mineral density. This is a protective effect of the G allele that contrasts with
its reproductive-tissue risk profile.
Breast cancer: A
meta-analysis of 34,721 subjects across 23 studies | Tan et al. Scientific Reports,
2021 found no significant association
between rs9340799 and breast cancer risk across all genetic models tested, settling
a previously contested question.
Practical Implications
For women, the strongest clinically actionable signals from rs9340799 are in the
reproductive domain: the GG genotype is associated with elevated endometriosis-related
infertility risk and IVF failure, and with greater severe pre-eclampsia susceptibility.
Heterozygous AG carriers show intermediate risk. The AA genotype is associated with
better ovarian responsiveness during IVF stimulation.
Women carrying the GG genotype who are planning pregnancy should discuss their genetic
profile with a reproductive specialist, particularly if IVF is anticipated. Early
referral and personalized FSH dosing protocols informed by this variant may improve
controlled ovarian hyperstimulation outcomes. GG carriers with symptoms suggestive of
endometriosis warrant proactive evaluation rather than symptom normalization.
For men, the G allele appears protective against infertility, suggesting sex-specific
regulatory effects on the reproductive axis.
Interactions
rs2234693 (ESR1 PvuII): rs9340799 and rs2234693 are in strong linkage disequilibrium
and are most informative as a haplotype. The C(PvuII)/G(XbaI) haplotype was associated
with approximately 5-fold elevated coronary artery disease risk in one Indian case-control
study. For reproductive outcomes, the T/A haplotype (rs2234693 T + rs9340799 A) appears
relevant to premature ovarian insufficiency. Compound action proposal: women carrying
both rs2234693 TT and rs9340799 GG genotypes may represent a subgroup with elevated
reproductive vulnerability warranting earlier fertility workup; evidence level moderate.
rs2046210 (ESR1 promoter): A 2024 study found rs2046210 GA heterozygosity
significantly increased endometriosis risk and elevated ESR1 expression in eutopic
endometrium, suggesting that multiple ESR1 regulatory variants contribute independently
to endometriosis susceptibility. Women carrying risk alleles at both rs9340799 and
rs2046210 may have compounded estrogen-signaling dysregulation.
rs7521902 (near WNT4): WNT4 signaling suppresses androgen production and supports
female reproductive development; its GWAS locus is one of the most replicated endometriosis
signals. Carrying risk alleles at both ESR1 and WNT4 loci may confer additive endometriosis
susceptibility, though formal interaction testing has not been published.
All Genotypes
No copies of the XbaI risk allele — normal estrogen receptor function
You carry two copies of the A allele at rs9340799, the common reference genotype associated with normal estrogen receptor alpha expression and signaling in reproductive tissues. About 44% of the global population shares this genotype. In IVF studies, the AA genotype has been associated with better ovarian responsiveness during controlled hyperstimulation — more follicles, mature oocytes, and better embryo quality — compared to GG carriers. This result is generally reassuring for reproductive function at this locus.
One copy of the XbaI G allele — modestly elevated reproductive risk
You carry one copy of the G allele at rs9340799. Heterozygous AG carriers show intermediate endometriosis-related risk compared to AA (lowest) and GG (highest) carriers under the codominant model. About 44% of the global population shares this genotype, making it the most common. The G allele is thought to modestly reduce estrogen receptor alpha expression in endometrial tissue, potentially affecting the implantation window and uterine responsiveness. For reproductive planning, one copy of the G allele warrants awareness rather than alarm.
Two copies of the XbaI G allele — elevated endometriosis and IVF-failure risk
You carry two copies of the G allele at rs9340799. The GG genotype was associated with a 4.67-fold increased risk of endometriosis-related infertility and a 3.33-fold increased risk of IVF failure in a case-control study. The same genotype was associated with elevated severe pre-eclampsia risk (OR 1.67) in a meta-analysis. About 11% of the global population carries this genotype. In IVF ovarian stimulation studies, the GG genotype was associated with fewer follicles, fewer mature oocytes, and lower embryo quality compared to AA carriers, suggesting reduced FSH responsiveness in the ovary. This variant is also present in the existing rs2234693 (ESR1 PvuII) entry, as both loci are in strong linkage disequilibrium and often studied as a haplotype.